MDVN can't justify a market cap of $4 billions with hardly $200 millions in revenue in 2013. And only 50% of the potential "earnings" on these revenues are MDVN's. It's a joke.
DNDN is coming back from the abyss and will take it's market share as expected.
The only potential problem for both MDVN and DNDN is the soon availability of Zytiga as generic.
Congratulations. You have consolidated into one post several pieces of misinformation promulgated in various posts ... but perhaps they were all yours.
My pleasure. The DNDN folks lost sleep over not locking in profits before the sudden 80% drop. Good luck.
MDVN very quickly could go lower than $15. All the market makers need is one piece of bad news to crush it. There's too much money to be made on the way down, the run is over on the up side.